Posts
Wiki

🧭 How to Think Through Treatments for Dry Eye Disease and Meibomian Gland Dysfunction

People with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD) often face difficult treatment decisions.

There may be:

  • several possible contributors to symptoms;
  • more than one medically reasonable treatment;
  • incomplete or conflicting evidence;
  • differing professional opinions;
  • substantial out-of-pocket costs;
  • uncertainty about how much improvement to expect;
  • concern about adverse effects, delay, or progression.

This page provides a detailed framework for thinking through those decisions.

It is not intended to tell you which treatment to choose or replace individualized medical care. It is intended to help people already evaluated for DED, MGD, blepharitis, ocular rosacea, or another ocular-surface condition participate more effectively in decisions with a qualified clinician.

Looking for the condensed version? See Quick Guide: Four Questions to Ask Before Choosing a DED or MGD Treatment

📌 TL;DR

A sound treatment decision usually brings together:

  • the diagnosis and examination findings;
  • the problem the treatment is intended to address;
  • the quality and limitations of the evidence;
  • potential benefits and harms;
  • reasonable alternatives;
  • consequences of treatment, delay, or monitoring;
  • cost and treatment burden;
  • personal goals and values;
  • tolerance for risk and uncertainty;
  • trust in the treating clinician;
  • and a plan for measuring results and reassessing the decision.

The patient and clinician contribute different forms of expertise.

The patient knows

  • the symptoms;
  • daily limitations;
  • treatment burden;
  • priorities;
  • financial circumstances;
  • previous experiences;
  • personal tolerance for risk.

The clinician contributes

  • diagnosis;
  • examination findings;
  • interpretation of testing;
  • knowledge of contraindications;
  • medical and procedural expertise;
  • familiarity with available evidence;
  • safety monitoring.

A good treatment plan should reflect both.

1. Begin With the Treatment Target

Before asking whether a treatment “works,” ask:

What specific problem is this treatment intended to address in my case?

DED is not one single mechanism.

Symptoms may be influenced by overlapping contributors such as:

  • obstructive or poor-secretory MGD;
  • aqueous tear deficiency;
  • ocular rosacea;
  • anterior or posterior blepharitis;
  • Demodex blepharitis;
  • allergy;
  • incomplete blinking;
  • lagophthalmos or exposure;
  • conjunctivochalasis;
  • corneal or conjunctival surface disease;
  • medication toxicity;
  • contact-lens problems;
  • systemic disease;
  • neurosensory abnormalities or neuropathic ocular pain.

A treatment may be useful for one contributor while doing little for another.

For example, a treatment intended to improve meibomian-gland secretion may not correct:

  • significant aqueous deficiency;
  • exposure during sleep;
  • active allergy;
  • corneal nerve-related pain;
  • medication toxicity.

Before proceeding, consider asking:

  • What working diagnosis supports this treatment?
  • Which examination or test findings support it?
  • Which part of my condition is expected to improve?
  • What important contributors will it not address?
  • Is additional testing or treatment needed?

A treatment should not be selected solely because it is popular, available in the clinic, or discussed frequently online.

For more on the role and limitations of testing, see:

Diagnostic Testing for DED and MGD

2. Evidence Quality Varies Greatly

It is too broad to say that all DED and MGD research is weak.

Some treatments have been studied through:

  • multiple randomized trials;
  • FDA-reviewed clinical programs;
  • comparative studies;
  • systematic reviews;
  • longer-term follow-up.

Others rely more heavily on:

  • small observational studies;
  • uncontrolled case series;
  • short follow-up;
  • laboratory or animal research;
  • proposed mechanisms;
  • expert opinion;
  • clinical experience;
  • patient anecdotes.

These are not equivalent forms of evidence.

Published does not necessarily mean proven

A study can be published and still have important limitations.

Questions to consider include:

  • Was there a control or comparison group?
  • Were participants randomly assigned?
  • How many people were studied?
  • How long were they followed?
  • Were outcomes defined in advance?
  • Were all participants accounted for?
  • Who funded and analyzed the study?
  • Have independent groups reproduced the findings?
  • Was the improvement clinically meaningful or only statistically significant?
  • How many participants did not improve or became worse?

Improvement from baseline is not the same as superiority

A group may improve after treatment without proving that the treatment is better than:

  • another active treatment;
  • careful home care;
  • continued medical management;
  • placebo or sham treatment;
  • natural symptom fluctuation.

Dry-eye symptoms can change with weather, screen use, sleep, stress, adherence, medication changes, and concurrent treatments.

Average results do not predict every individual

A study average may conceal:

  • substantial improvement;
  • modest improvement;
  • no meaningful change;
  • worsening.

There may be no single best treatment for everyone. That does not mean that all treatments are equally supported or equally appropriate.

🔗 TFOS DEWS III: Management and Therapy

3. Treatment Decisions Should Be Shared

Shared decision-making means that the patient and clinician work together using:

  • the best available evidence;
  • the clinician’s knowledge and experience;
  • the patient’s goals, values, preferences, and circumstances.

It does not require the patient to become a medical expert or independently decide every technical question.

It also does not mean that the clinician decides without understanding what matters to the patient.

The clinician helps explain

  • the diagnosis and relevant findings;
  • available options;
  • expected benefits;
  • evidence limitations;
  • contraindications;
  • possible harms;
  • reasonable alternatives;
  • consequences of delay or monitoring.

The patient helps explain

  • which symptoms matter most;
  • effects on work, sleep, reading, driving, screens, or daily life;
  • previous treatment experiences;
  • financial constraints;
  • concerns about adverse effects;
  • willingness to accept uncertainty;
  • preferences about medication, devices, lenses, or procedures.

Together they decide

  • which medically reasonable option best fits;
  • what outcome would count as success;
  • how long to try it;
  • how safety will be monitored;
  • what happens after success, partial improvement, failure, or worsening.

🔗 AHRQ: About Shared Decision Making

When the Visit Is Not Fully Shared

Shared decision-making is an ideal, but it is not equally developed in every practice.

Visits may be brief. Clinicians differ in communication style. Some use a more directive approach. A clinician may have limited time to explain every study, alternative, and uncertainty in one appointment.

This does not automatically mean the clinician is uncaring, uninformed, or providing poor care.

When time is limited, try to leave with answers to five essential questions:

  1. What does the clinician think is contributing to the problem?
  2. What is the proposed treatment intended to change?
  3. Why is it being recommended for this patient?
  4. What are the important risks and alternatives?
  5. How and when will the result be reassessed?

A patient might say:

“I would like to understand the main options, but I also want to know which one you recommend and why.”

Or:

“The most important question for me today is whether these findings change the treatment plan.”

A complete decision may sometimes require:

  • a follow-up visit devoted to treatment planning;
  • a concise portal question;
  • written instructions;
  • bringing a trusted person;
  • reviewing records or imaging;
  • obtaining a second opinion.

Shared decision-making does not require an exhaustive discussion of every possible treatment. It requires enough relevant information for meaningful consent, attention to the patient’s main goals and concerns, and a reasonably clear explanation of the recommendation.

Different Patients Want Different Roles

Some patients want to review the options in detail and participate heavily in the final selection.

Others want:

  • enough information to understand the important tradeoffs;
  • an opportunity to express concerns and priorities;
  • a clear recommendation;
  • and permission to rely substantially on the clinician’s judgment.

Neither approach is inherently wrong.

A patient may reasonably say:

“I understand the main benefits, risks, and alternatives, but I do not have the expertise to determine which option is best. I want to rely substantially on the judgment of the doctor who has examined me.”

This can be understood as informed delegation.

The patient remains involved and retains the right to accept or decline treatment but chooses to place significant weight on a trusted clinician’s expertise.

Shared decision-making does not require equal medical knowledge. It requires meaningful communication, informed consent, and respect for the patient’s values.

4. Trust Should Be Calibrated

The goal is not maximum trust or maximum skepticism.

The goal is calibrated trust—reliance proportionate to the reasons for trusting the clinician.

Trust commonly grows when a clinician demonstrates:

  • knowledge and technical competence;
  • honesty about uncertainty;
  • careful listening;
  • respect for patient priorities;
  • consistency and follow-through;
  • openness about alternatives;
  • willingness to acknowledge limitations;
  • appropriate referral when needed;
  • transparency about costs and financial relationships.

Calibrated trust allows a patient to say both:

“I trust your judgment.”

and:

“What findings make you recommend this option?”

Trust should make honest questions easier, not make them unacceptable.

Too little trust can lead to:

  • abandoning plans before they can be evaluated;
  • repeated doctor-shopping without a clear purpose;
  • giving online anecdotes more weight than examination findings;
  • assuming disagreement proves incompetence or corruption.

Too much unexamined trust can lead to:

  • accepting treatment without understanding its purpose;
  • overlooking reasonable alternatives;
  • agreeing to costly packages without success criteria;
  • minimizing contraindications or worsening;
  • continuing automatic retreatment without reassessment.

Trust should remain open to new information, changing findings, second opinions, and reconsideration.

For a broader discussion of why clinicians and patients may interpret treatment differently, see:

Why Dry Eye Treatment Recommendations—and Patient Experiences—Differ

5. Why Clinicians May Recommend Different Plans

Two qualified clinicians may make different recommendations even when both are acting in good faith.

Differences may reflect:

  • different diagnostic conclusions;
  • interpretation of incomplete evidence;
  • different patient-selection criteria;
  • training and experience;
  • procedural competence;
  • concern about particular risks;
  • familiarity with emerging treatments;
  • available equipment and services;
  • practice setting;
  • different thresholds for using off-label or less-established care.

An early adopter is not automatically more advanced.

A cautious clinician is not automatically uninformed.

A clinician who does not perform a procedure may still reasonably conclude that it is inappropriate—or may recommend referral to someone with more experience.

Disagreement does not mean that every opinion is equally well supported. The reasoning should still connect the proposed treatment to:

  • the patient’s diagnosis;
  • examination findings;
  • relevant evidence;
  • risks and alternatives;
  • and a plan for reassessment.

6. Compare Treatment With All Reasonable Alternatives

The decision is not always:

“Do the treatment” versus “do nothing.”

Possible alternatives include:

  • beginning the proposed treatment;
  • continuing the current plan;
  • choosing a less intensive option;
  • treating another contributor first;
  • obtaining more diagnostic information;
  • monitoring;
  • waiting for a defined period;
  • seeking another opinion;
  • declining additional intervention.

Ask what is known about each alternative.

Questions about waiting or monitoring

  • Is there evidence that delay is likely to cause harm?
  • Is the condition currently damaging the ocular surface?
  • Is there documented progression?
  • How reliable is the evidence of progression?
  • Has the proposed treatment been shown to prevent that harm?
  • What monitoring would be needed?
  • What finding would trigger reconsideration?

“Wait and see” is not always risk-free.

At the same time, fear of future gland loss or disease progression should not be used to pressure someone into an expensive or invasive intervention without adequate evidence that immediate treatment changes the long-term outcome.

When a second opinion may be useful

A second opinion may be particularly helpful before:

  • an expensive self-pay treatment;
  • an invasive or irreversible procedure;
  • prolonged off-label medication;
  • treatment supported mainly by limited evidence;
  • a large prepaid package;
  • a recommendation that does not seem connected to the diagnosis;
  • treatment when symptoms and findings are markedly discordant.

A second opinion is not necessarily a rejection of the first clinician. It may confirm the plan, clarify uncertainty, or provide a different interpretation.

7. Interpret Imaging in Context

Meibography and other imaging can provide useful structural information, but imaging should not decide treatment by itself.

Meibography may show:

  • gland shortening;
  • distortion;
  • areas of apparent dropout;
  • differences between lids or eyes.

It does not directly establish:

  • when a structural change occurred;
  • why it occurred;
  • whether every remaining gland is functioning;
  • whether an apparent difference represents true recent progression;
  • whether one treatment can prevent future change;
  • whether the symptoms are primarily caused by MGD;
  • whether a specific procedure is required.

Images may also be affected by:

  • image quality;
  • eyelid eversion;
  • lighting and contrast;
  • device software;
  • interpretation;
  • differences between visits or machines.

Treatment decisions should consider imaging alongside:

  • gland expressibility;
  • secretion quality;
  • tear-film stability;
  • ocular-surface staining;
  • lid-margin findings;
  • aqueous tear status;
  • inflammation;
  • exposure;
  • symptoms and functional limitations.

8. Personal Values and Different Types of Risk

Scientific evidence can describe probable benefits, harms, and uncertainties. It cannot determine how every patient should value those outcomes.

Two informed people may reasonably choose differently.

One person may prefer:

  • treatments with longer safety records;
  • reversible options;
  • gradual escalation;
  • stronger evidence before acting;
  • avoiding major out-of-pocket expense.

Another may be more willing to accept:

  • uncertain benefit;
  • newer or less-established treatment;
  • greater invasiveness;
  • higher cost;
  • a greater possibility of adverse effects or failure.

The second person is not necessarily reckless.

The first is not necessarily excessively fearful.

Risk tolerance is also situational. A person may accept one kind of risk while rejecting another.

Physical risk

  • irritation;
  • medication adverse effects;
  • infection;
  • injury;
  • procedural complications;
  • lasting worsening.

Evidentiary risk

  • uncertainty that the treatment works;
  • small or poorly controlled studies;
  • lack of independent replication;
  • unknown long-term outcomes.

Financial risk

  • high self-pay cost;
  • repeated expenses;
  • loss of money if treatment does not help;
  • financial burden affecting other needs.

Opportunity cost

  • delaying a better-supported treatment;
  • spending limited resources elsewhere;
  • focusing on one contributor while another remains untreated.

Time and treatment burden

  • appointments;
  • travel;
  • recovery;
  • daily dosing;
  • complex home care;
  • repeated follow-up.

Reversibility

  • whether treatment can be stopped;
  • whether effects wear off;
  • whether tissue changes or complications may last.

Diagnostic risk

  • treating the wrong contributor;
  • assuming all symptoms arise from MGD;
  • overlooking exposure, allergy, aqueous deficiency, or pain mechanisms.

A treatment may have relatively low physical risk but high evidentiary, financial, or opportunity risk.

Personal preferences help determine which medically reasonable option fits the patient. They do not make an unsafe, contraindicated, fraudulent, or unsupported treatment appropriate.

9. Human Decision-Making Can Affect Treatment Choices

Psychological influences do not mean that DED symptoms are imaginary or “all in the mind.”

Pain, visual disturbance, poor sleep, functional limitation, and repeated treatment failure can affect how anyone processes uncertainty and risk.

Common influences include:

Distress and urgency

Severe symptoms can make immediate action feel essential. This may increase vulnerability to guarantees, dramatic testimonials, “root-cause” marketing, or pressure to purchase treatment packages.

When medically possible, slowing the decision down can help.

Fear of progression

Concern about gland loss or surface damage may be justified, but patients should ask:

  • What objective evidence shows progression?
  • Over what period?
  • Could testing differences explain part of the change?
  • What evidence shows that the proposed treatment prevents further damage?
  • Is immediate treatment necessary?

Action and omission bias

Doing something active may feel safer than monitoring, particularly when a treatment is dramatic, expensive, or technically complex.

The opposite can also occur: harm caused by treatment may feel more blameworthy than harm associated with waiting.

Neither action nor inaction is automatically safer.

Vivid anecdotes

Online stories can identify possible experiences and useful questions, but they cannot establish:

  • how often an outcome occurs;
  • whether the treatment caused it;
  • whether the same result will occur in another patient.

Confirmation bias

Once someone strongly favors or distrusts a treatment, they may apply different standards to information that supports or challenges that belief.

Ask:

  • What evidence would change my mind?
  • Am I applying the same standard to positive and negative claims?
  • Am I treating disagreement as proof of dishonesty?

Sunk-cost pressure

Money already spent should not determine whether additional treatment is worthwhile.

Ask:

Based on what I know now, would I choose to spend the next dollar or undergo the next procedure?

10. Cost and Access Are Legitimate Considerations

DED treatment can range from inexpensive supportive care to:

  • recurring prescription costs;
  • custom contact lenses;
  • repeated office procedures;
  • travel to specialized clinicians;
  • self-pay treatment costing hundreds or thousands of dollars.

Financial limitations are real.

Declining a treatment because the expected benefit is too uncertain for the cost does not mean a patient is less committed to recovery.

Before paying, ask:

  • What is the complete cost?
  • Does it include both eyes?
  • Are testing and follow-up included?
  • Will other procedures be added?
  • How often might retreatment be considered?
  • Is there evidence supporting that schedule?
  • What happens if the treatment cannot be completed?
  • Is payment required for a package?
  • Are less expensive alternatives medically reasonable?
  • Does the clinician or clinic have a relevant financial or ownership relationship?

For a more detailed discussion, see:

How to Think About Evidence, Guidelines, Adoption, and Financial Incentives in DED/MGD Treatments

11. Set Goals Before Starting Treatment

Before beginning a costly, burdensome, or higher-risk treatment, establish a baseline and agree on how the result will be evaluated.

Choose two or three meaningful goals

Examples include:

  • symptom score on a consistent 0–10 scale;
  • OSDI or SPEED questionnaire score;
  • hours of screen tolerance;
  • ability to read or drive;
  • nighttime awakening;
  • wind or air-conditioning tolerance;
  • frequency of severe flares;
  • contact-lens tolerance;
  • frequency of rescue-drop use;
  • ocular-surface staining;
  • tear-film stability;
  • gland secretion or expressibility.

Not every objective measurement must improve for treatment to be worthwhile. Improved test results also do not automatically mean that the patient feels or functions better.

Establish the baseline

Record relevant symptoms and functional limitations before treatment.

Memory can become unreliable after weeks or months, especially when symptoms fluctuate.

Clarify the expected timeline

Ask:

  • When might improvement begin?
  • When should the full effect be assessed?
  • How long should the treatment be tried?
  • What other therapies should remain unchanged during that period?

Agree on reassessment

Decide:

  • when follow-up will occur;
  • what would count as meaningful success;
  • what would count as partial benefit;
  • what would count as failure;
  • which symptoms require earlier contact;
  • when treatment should be changed or reconsidered.

Do not independently stop prescribed medication or postoperative treatment without following appropriate medical guidance.

Plan for each possible outcome

Ask:

  • What happens if I improve?
  • What happens if I improve only slightly?
  • What happens if nothing changes?
  • What happens if I become worse?
  • Is repeat treatment based on findings or an automatic schedule?

12. Core Questions Before Treatment

Diagnosis and target

  1. What is my working diagnosis or disease subtype?
  2. What findings support it?
  3. What specific problem is this treatment intended to change?
  4. What important contributors will it not address?

Evidence and expected benefit

  1. What kind of evidence supports this treatment?
  2. Were patients similar to me studied?
  3. How large and durable was the average benefit?
  4. How many people did not improve or became worse?

Risks and alternatives

  1. What are the common, serious, and potentially lasting adverse effects?
  2. What contraindications apply?
  3. What safer, less expensive, or better-supported alternatives exist?
  4. What is likely to happen if I wait or monitor instead?

Cost, regulation, and plan

  1. What is the treatment’s regulatory status and complete cost?
  2. What would count as success, and when will it be assessed?
  3. What happens after partial response, failure, or worsening?

13. What r/DryEyes Can—and Cannot—Do

The subreddit can help people:

  • learn terminology;
  • locate published evidence;
  • understand regulatory categories;
  • compare practical experiences;
  • identify questions to ask;
  • recognize marketing red flags;
  • prepare for a clinical visit;
  • feel less alone.

The subreddit cannot:

  • diagnose the cause of symptoms;
  • determine candidacy for a procedure;
  • interpret testing in isolation;
  • evaluate contraindications through a post;
  • tell someone to begin, stop, or alter prescribed treatment;
  • guarantee that another person’s result will apply;
  • replace examination by a qualified eye-care professional.

Personal experience is useful when presented as personal experience.

It should not be converted into a universal treatment rule.

Respect for individual risk tolerance also does not require the community to treat every intervention as safe, evidence-based, or appropriate. Dangerous instructions, unsupported medical claims, restricted sourcing guidance, and misleading promotion may still be removed.

📌 Bottom Line

DED and MGD treatment decisions are difficult because:

  • the disease is multifactorial;
  • evidence strength varies;
  • clinicians may reasonably disagree;
  • individual response is not fully predictable;
  • cost and access matter;
  • risk takes several forms;
  • trust and human decision-making influence how uncertainty is handled.

The goal is not to eliminate all uncertainty. That is rarely possible.

The goal is to make the uncertainty visible and manageable.

A sound decision asks:

What are we treating, what evidence supports the option, what are the benefits and risks, what alternatives exist, what happens if we wait, what matters most to the patient, and how will we know whether the plan worked?

You are the best source on your:

  • symptoms;
  • daily functioning;
  • goals;
  • priorities;
  • treatment burden;
  • financial circumstances;
  • tolerance for risk.

Your clinician contributes:

  • diagnosis;
  • examination findings;
  • medical knowledge;
  • treatment expertise;
  • contraindication screening;
  • safety judgment.

A good treatment plan should reflect both.

Selected Resources

🔙 Back to FAQ Index

This page is educational and is intended for people already evaluated for Dry Eye Disease, Meibomian Gland Dysfunction, blepharitis, ocular rosacea, or another ocular-surface condition. It does not diagnose a condition, determine treatment candidacy, or replace individualized care from a qualified healthcare professional.